CoChat

Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission

Open access
Bocchia, Monica, Sicuranza, Anna, Abruzzese, Elisabetta, Iurlo, Alessandra, Sirianni, Santina, Gozzini, Antonella, Galimberti, Sara, Aprile, Lara, Martino, Bruno, Pregno, Patrizia, Sorà, Federica, Alunni, Giulia, Fava, Carmen, Castagnetti, Fausto, Puccetti, Luca, Breccia, Massimo, Cattaneo, Daniele, Defina, Marzia, Mulas, Olga, Baratè, Claudia, Caocci, Giovanni, Sica, Simona, Gozzetti, Alessandro, Luciano, Luigiana, Crugnola, Monica, Annunziata, Mario, Tiribelli, Mario, Pacelli, Paola, Ferrigno, Ilaria, Usala, Emilio, Sgherza, Nicola, Rosti, Gianantonio, Bosi, Alberto, Raspadori, Donatella · 2018 · Frontiers in Oncology
Cited by 108

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Chronic Myeloid Leukemia (CML) patients in sustained “deep molecular response” (DMR) may stop TKI treatment without disease recurrence; however, half of them lose molecular response shortly after TKI withdrawing. Well-defined eligibility criteria to predict a safe discontinuation up-front are still missing. Relapse is probably due to residual quiescent TKI resistant leukemic stem cells (LSCs) supposedly transcriptionally low/silent and not easily detectable by BCR-ABL1 qRT-PCR. Bone marrow Ph+CML CD34+/CD38-LSCs were found to specifically co-express CD26(dipeptidylpeptidase-IV). We explored feasibility of detecting and quantifying CD26+LSCs by flow-cytometry in peripheral blood. Over 400 CML patients (at diagnosis and during/after therapy) entered this cross-sectional study in which CD26 expression was evaluated by a standardized multiparametric flow-cytometry analysis on PB CD45+/CD34+/CD38- stem cell population. All 120 CP-CML patients at diagnosis showed measurable PB CD26+LSCs (median 19.20/µL, range 0.27-698.6). PB CD26+LSCs were also detectable in 169/236 (71.6%) CP-CML patients in first-line TKI treatment (median 0.014 cells/µL; range 0.0012-0.66) and in 74/112 (66%) additional patients studied on treatment free remission (TFR) (median 0.015/µL; range 0.006-0.76). Notably no correlation between BCR-ABL/ABLIS ratio and number of residual LSCs was found both in patients on or off TKIs. This is the first evidence that “circulating” CML LSCs persist in the majority of CML patients in molecular response while on TKI treatment and even after TKI discontinuation. Prospective studies evaluating the dynamics of PB CD26+LSCs during TKI treatment and the role of a “stem cell response” threshold to achieve and maintain TFR are ongoing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fonc.2018.00194

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 108

Metadata

Authors
Bocchia, M., Sicuranza, A., Abruzzese, E., Iurlo, A., Sirianni, S., Gozzini, A., Galimberti, S., Aprile, L., Martino, B., Pregno, P., Sorà, F., Alunni, G., Fava, C., Castagnetti, F., Puccetti, L., Breccia, M., Cattaneo, D., Defina, M., Mulas, O., Baratè, C., Caocci, G., Sica, S., Gozzetti, A., Luciano, L., Crugnola, M., Annunziata, M., Tiribelli, M., Pacelli, P., Ferrigno, I., Usala, E., Sgherza, N., Rosti, G., Bosi, A., & Raspadori, D.
Venue
Frontiers in Oncology
Published
2018-05-30
Volume
8
Pages
194-194
ISSN
2234-943X (ISSN-L)
OpenAlex
W2805227060
Cited by
108
References
3
FWCI
9.42
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.